Tresiba (insulin degludec) is a prescription drug that’s used to manage high blood sugar in people with diabetes. Tresiba’s cost may depend on your dosage, your health insurance, and the pharmacy you ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

Tresiba (insulin degludec) is a brand-name drug that’s prescribed for diabetes. The medication is available as a liquid vial and a prefilled injection pen. The cost of Tresiba with and without ...

Tresiba and Lantus are both long-acting insulins used to manage blood sugar levels in people with type 1 or type 2 diabetes. (For more information on each’s drug uses, see the “What are Tresiba and ...

PLAINSBORO, N.J., Sept. 25, 2015 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for ...

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...

The study's lead author said that complications from cardiovascular disease remain an unmet clinical challenge in type 2 diabetes. Insulin degludec, the ultra long-acting basal insulin from Novo ...

Insulin degludec (Tresiba) is a long-acting insulin analogue given once daily as a subcutaneous injection for basal insulin therapy. It has a duration of action beyond 42 hours within the therapeutic ...

PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insulin, Tresiba® (insulin degludec injection), a ...

Novo Nordisk has received European approval for two new diabetes products – Tresiba and Ryzodeg – that are central to its growth plans for the next few years. Tresiba (insulin degludec) and Ryzodeg ...

People with diabetes have been hit with a five-month shortage of a vital medication. The Tresiba FlexTouch U100 insulin pen, which is manufactured by global pharmaceutical giant Novo Nordisk, is ...